AOD-9604 is a modified fragment of human growth hormone (hGH 176-191) that has been studied specifically for its lipolytic (fat-reducing) properties without the broader metabolic effects associated with full-length growth hormone. Current research suggests it may stimulate fat breakdown and inhibit lipogenesis, but human clinical data remains limited, and its long-term safety profile has not been fully established.
AOD-9604 has become one of the most discussed fat loss peptides in the research community, drawing attention for its targeted mechanism of action and relatively favorable safety profile observed in early studies. Originally developed by Metabolic Pharmaceuticals in Australia, this peptide represents a focused approach to investigating how growth hormone-derived fragments interact with adipose tissue. This comprehensive research guide covers the science behind AOD-9604, its mechanism of action, dosing protocols reported in the literature, and everything a researcher needs to know before beginning an investigation into this compound.
What Is AOD-9604? Mechanism and Background
AOD-9604, also known as the anti-obesity drug 9604, is a synthetic peptide analog corresponding to the C-terminal fragment of human growth hormone — specifically amino acids 176 through 191 — with an added tyrosine residue at the N-terminus. The compound was developed based on research indicating that the fat-reducing effects of growth hormone are governed by a distinct region of the molecule, separate from the domains responsible for growth promotion and insulin resistance.
The mechanism of action centers on the stimulation of lipolysis (the breakdown of stored triglycerides into free fatty acids and glycerol) and the simultaneous inhibition of lipogenesis (the formation of new fat). Critically, studies have indicated that AOD-9604 achieves these effects without activating the growth hormone receptor in a way that would influence IGF-1 levels, blood glucose homeostasis, or tissue growth. This selectivity is what differentiates it from full-length hGH administration and is the primary reason it has attracted interest as a targeted fat loss research compound.
In preclinical models, AOD-9604 demonstrated significant reductions in body fat in obese mice and Zucker rats without affecting lean mass, food intake, or circulating IGF-1 concentrations. A pivotal observation was that the peptide appeared to upregulate beta-3 adrenergic receptor activity in adipose tissue, enhancing the lipolytic cascade. Early human trials conducted by Metabolic Pharmaceuticals showed modest but statistically significant fat loss over 12-week periods, though the compound ultimately did not progress through full regulatory approval as a pharmaceutical drug.
Reported Dosing Protocols in the Research Literature
Dosing information for AOD-9604 comes primarily from clinical trial data and anecdotal research community reports. The following table summarizes the most commonly referenced protocols:
| Protocol | Daily Dose | Frequency | Duration | Administration |
|---|---|---|---|---|
| Clinical Trial (Phase 2) | 250 mcg – 1 mg | Once daily | 12 weeks | Oral |
| Common Research Protocol (Subcutaneous) | 250 – 300 mcg | Once daily | 8 – 12 weeks | Subcutaneous injection |
| Higher-End Research Protocol | 500 mcg | Once daily | 8 – 12 weeks | Subcutaneous injection |
| Split-Dose Protocol | 250 mcg x 2 | Twice daily | 8 – 12 weeks | Subcutaneous injection |
Most research protocols administer AOD-9604 in the morning on an empty stomach, as the absence of elevated insulin levels may support its lipolytic activity. The subcutaneous route is preferred in research settings because it offers more predictable bioavailability compared to the oral route used in earlier clinical trials. Some researchers report running the compound in cycles of 8 to 12 weeks, followed by a washout period of equal length, though the optimal cycling strategy has not been rigorously established in peer-reviewed literature.
What You Will Need
Before beginning this protocol, researchers typically gather the following supplies: bacteriostatic water for reconstitution, insulin syringes for precise measurement, alcohol prep pads for sterile technique, and a sharps container for safe disposal. Proper peptide storage cases or a dedicated mini fridge help maintain compound integrity between uses. AOD-9604, like most lyophilized peptides, should be stored at 2–8°C (36–46°F) before and after reconstitution. Once reconstituted with bacteriostatic water, the solution is generally considered stable for up to 25–30 days under refrigeration. Researchers should avoid repeated freeze-thaw cycles, as this can degrade the peptide and compromise research outcomes.
Reconstitution and Handling Protocol
Reconstitution follows standard peptide preparation practices. Using an insulin syringe, slowly inject bacteriostatic water along the inside wall of the vial, allowing it to run down and gently dissolve the lyophilized powder. Do not shake the vial — instead, swirl gently or allow it to sit until fully dissolved. A common reconstitution ratio is 2 mL of bacteriostatic water per 5 mg vial, yielding a concentration of 2.5 mg/mL (or 250 mcg per 0.1 mL). Before each draw, clean the vial stopper with an alcohol prep pad to maintain sterile conditions.
Injection sites typically include the abdominal subcutaneous region (rotating injection points), the outer thigh, or the upper arm. Rotation of injection sites is important to prevent localized tissue irritation. Used syringes and needles should always be disposed of in a sharps container — never recapped or placed in general waste.
Observed Effects and Research Outcomes
The Phase 2b clinical trial conducted by Metabolic Pharmaceuticals in 2004 enrolled over 300 obese participants and tested oral AOD-9604 at doses of 1 mg, 5 mg, 10 mg, and 20 mg per day. The 1 mg group showed the most statistically significant weight loss compared to placebo at 12 weeks, a finding that surprised researchers and suggested a non-linear dose-response relationship. No significant adverse effects on glucose metabolism, IGF-1, or cardiac parameters were observed across dosing groups.
Anecdotal reports from the research community frequently describe subtle but consistent body composition improvements when AOD-9604 is combined with caloric control and regular exercise. Unlike compounds that stimulate the HPA axis or dramatically alter appetite, AOD-9604 appears to work gradually and is often described as a “background” lipolytic agent rather than a dramatic intervention. Researchers have noted that its effects may be most apparent in individuals who have already optimized their baseline nutrition and training protocols.
It is worth noting that in 2010, the Therapeutic Goods Administration (TGA) in Australia gave AOD-9604 Generally Recognized As Safe (GRAS) status for use as a food additive, which, while not an endorsement of efficacy for fat loss, suggests confidence in its safety profile at the doses studied.
Track your peptide protocol for free
Log every dose, cost, weight change, and observation in one place. Free web app — no credit card needed.
Optimizing Results: Supporting Factors in Fat Loss Research
Researchers investigating AOD-9604 often examine it within the context of broader metabolic optimization. Sleep quality plays a critical role in lipolytic signaling and hormonal regulation, and many researchers supplement with magnesium glycinate to support deep sleep and recovery — both of which directly influence fat metabolism and cortisol regulation. Elevated cortisol, in particular, can promote visceral fat storage and counteract the lipolytic effects being studied. For this reason, some protocols include ashwagandha (Withania somnifera), which has demonstrated cortisol-modulating effects in multiple randomized controlled trials.
Chronic low-grade inflammation is another variable that can confound fat loss research outcomes. Omega-3 fish oil supplementation, specifically EPA and DHA at combined doses of 2–3 grams daily, has been shown to reduce inflammatory markers like C-reactive protein and IL-6, creating a more favorable metabolic environment. Similarly, maintaining adequate vitamin D3 levels (targeting 40–60 ng/mL in serum) supports immune function and has been associated with improved body composition outcomes in observational studies.
Complementary Research Tools and Supplements
Beyond direct supplementation, researchers frequently incorporate recovery modalities that may enhance metabolic function and tissue health. Cold plunge or ice bath protocols, typically 2–5 minutes at 50–59°F (10–15°C), have been studied for their effects on brown adipose tissue activation and norepinephrine release — both of which are relevant to fat oxidation pathways. Red light therapy (photobiomodulation at 630–850 nm wavelengths) is another tool gaining traction in research settings, with emerging evidence suggesting it may support mitochondrial function and adipocyte metabolism. For researchers interested in cellular energy and longevity, NMN (nicotinamide mononucleotide) supplementation is being investigated for its role in boosting NAD+ levels, which decline with age and are integral to metabolic processes including fatty acid oxidation.
Where to Source
When sourcing AOD-9604 for research, quality and purity verification are non-negotiable. Researchers should look for vendors who provide third-party testing results and publicly available Certificates of Analysis (COAs) confirming peptide purity, typically at or above 98%. EZ Peptides (ezpeptides.com) is a reputable source that meets these criteria, offering third-party tested peptides with COAs available for each batch. Use code PEPSTACK for 10% off at EZ Peptides. When evaluating any peptide vendor, confirm that testing covers identity verification (via mass spectrometry), purity assessment (via HPLC), and endotoxin/sterility screening where applicable.
Frequently Asked Questions
Q: Does AOD-9604 affect growth hormone levels or IGF-1?
A: Based on available clinical and preclinical data, AOD-9604 does not appear to significantly alter circulating growth hormone or IGF-1 levels. This is a key differentiator from exogenous hGH administration. The fragment appears to act on adipose tissue through a mechanism that is independent of the classical GH receptor signaling pathway responsible for growth and insulin resistance.
Q: Can AOD-9604 be combined with other peptides?
A: Some research protocols examine AOD-9604 in combination with other compounds, such as CJC-1295 or ipamorelin. However, there is limited published data on the pharmacokinetic interactions or synergistic effects of these combinations. Researchers should approach stacking conservatively and log all variables carefully, as combining compounds introduces confounding factors that complicate the interpretation of outcomes.
Q: What are the most commonly reported side effects of AOD-9604?
A: In clinical trials, AOD-9604 demonstrated a side effect profile comparable to placebo. The most commonly reported issues were mild injection site reactions (redness, minor swelling) and occasional headaches. No clinically significant changes in blood glucose, insulin sensitivity, liver enzymes, or cardiovascular markers were observed. However, long-term safety data beyond 12 weeks remains sparse, and researchers should monitor relevant biomarkers throughout any extended protocol.
Q: How quickly do researchers typically observe measurable changes?
A: Most anecdotal research reports indicate that observable body composition changes begin to emerge around weeks 4–6 of consistent daily administration, with more pronounced effects by weeks 8–12. AOD-9604 is generally regarded as a gradual-acting compound, and researchers emphasize that caloric balance, exercise, and sleep quality significantly influence the magnitude of results.
This article is for research and informational purposes only. Nothing on PepStackHQ constitutes medical advice. Consult a qualified healthcare professional before beginning any research protocol.